Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma research hub

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

This study is testing a new treatment called nivolumab for children and adults with a type of cancer called ALK+ anaplastic large cell lymphoma that has come back or isn't responding to other treatments. It aims to see how well it works.